Clinical Trials Logo
  1. Home
  2. Skin Irritation
  3. NCT01887860
  4. Details
NCT01887860 Clinical Trial

Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50

Skin Irritation Clinical Trial

Official title:
Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Occlusive Patch)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01887860
Other study ID # GLI.04.SRE.US10232c
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2012

Study information
Verified date June 2013
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determine if Cetaphil Daily Facial Moisturizer SPF 50 proves to be a contact sensitizer or irritant in certain individuals.

Recruitment information / eligibility
Status Completed
Enrollment 100
Est. completion date
Est. primary completion date January 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Not currently under a doctor's care - Free of dermatological or systemic disorder which would interfere with the results - Free of any acute or chronic disease - Will complete a preliminary medical history form and are in general good health - Can read, understand, and sign informed consent Exclusion Criteria: - Under 18 years old - Currently under doctor's care - Currently taking any medication - History of acute or chronic disease - Diagnosed with chronic skin allergies - Pregnant or lactating

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Cetaphil Daily Facial Moisturizer SPF 50
Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks

Locations
Country Name City State
United States AMA Laboratories New City New York

Sponsors (1)
Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Area of erythema and edema measured 9 consecutive 24hr exposures for every Monday, Wednesday, and Friday for 3 consecutive weeks 3 consecutive weeks
See also
  Status Clinical Trial Phase
Completed NCT01806831 - Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment N/A
Completed NCT02297841 - Repeated Insult Patch Test of Personal Lubricants N/A
Completed NCT02968446 - Effect of Vitamin D After Application With Valchlor Early Phase 1
Completed NCT03397862 - A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System Phase 1
Unknown status NCT01821274 - A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design Phase 1
Completed NCT01892657 - Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test Phase 4
Withdrawn NCT02400320 - Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol Phase 4
Not yet recruiting NCT02645110 - Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations N/A
Completed NCT01887808 - Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30 N/A
Completed NCT01888887 - Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser N/A
Completed NCT01892410 - Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash N/A
Completed NCT01892423 - Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion N/A